On September 16, Edwards Lifesciences rose 3.08% in regular trading, trading at $88.36/share, with turnover of $77.65 million. The rally was primarily driven by the recent landing of the updated Medicare national coverage decision for transcatheter aortic valve replacement (TAVR), combined with the company's reaffirmation of its full-year financial outlook.

Edwards Lifesciences maintained its full-year adjusted EPS guidance of $2.95 to $3.05 and revenue expectations of $6.6 billion to $6.9 billion following the Medicare TAVR decision, while noting the revised coverage policy may require time to take full effect. The company also plans to share long-term financial projections at an investor conference in December. RBC Capital Markets highlighted that the TAVR coverage expansion could drive approximately 5% growth in national procedure volumes, with ACC/AHA guideline updates creating a favorable setup for growth acceleration.

Analyst sentiment has been broadly positive, with UBS upgrading to Buy with a $110 price target, Argus raising its target to $115, and multiple other firms adjusting targets higher. The stock also benefits from strong Q2 results, where adjusted EPS of $0.78 beat the $0.74 consensus by 5.4% on revenue of $1.74 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)